KLRD1 and chronic myelogenous leukemia, BCR-ABL1 positive: The levels of expression of some CD94/NKG2 receptors have been related to the antileukemic control during TFR, such as NKG2A downregulation [24] and NKG2C upregulation [25], which have been associated with reduced CML relapse during treatment interruption.